Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2019
[The influence of nooclerin on the structure of sleep disturbances in children with tension headaches].
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shipilova E M, Nesterovsky Yu E
Аннотация
AIM: To study the effects of nooclerin (deanol aceglumate) on the structure of sleep disturbances in children with tension-type headache (TTH).
MATERIAL AND METHODS: A blind randomized placebo-controlled study of the efficacy of nooclerin (deanol aceglumate), prescribed for 2 months to prevent TTH, was carried out. The study included 60 patients (30 boys and 30 girls), aged 9-16 years, with TTH. Patients were randomized into the nooclerin group (n=30) and the placebo group (n=30). Sleep disturbances were assessed before and after treatment with the Sleep Disturbance Scale for Children (SDSC).
RESULTS: There was a significant positive dynamics (reduced total score on SDSC (p<0.001) and a significant decrease in the scores on scales 'Disorders of initiating and maintaining sleep', 'Disorders of excessive somnolence' (p<0.001), 'Sleep wake transition disorders' (p<0.01)) in the nooclerin group. No significant positive changes were detected in the placebo group.
CONCLUSION: An anxiolytic action of nooclerin was confirmed. Further studies of the drug in child neurology and psychiatry using larger groups of patients are needed.
MATERIAL AND METHODS: A blind randomized placebo-controlled study of the efficacy of nooclerin (deanol aceglumate), prescribed for 2 months to prevent TTH, was carried out. The study included 60 patients (30 boys and 30 girls), aged 9-16 years, with TTH. Patients were randomized into the nooclerin group (n=30) and the placebo group (n=30). Sleep disturbances were assessed before and after treatment with the Sleep Disturbance Scale for Children (SDSC).
RESULTS: There was a significant positive dynamics (reduced total score on SDSC (p<0.001) and a significant decrease in the scores on scales 'Disorders of initiating and maintaining sleep', 'Disorders of excessive somnolence' (p<0.001), 'Sleep wake transition disorders' (p<0.01)) in the nooclerin group. No significant positive changes were detected in the placebo group.
CONCLUSION: An anxiolytic action of nooclerin was confirmed. Further studies of the drug in child neurology and psychiatry using larger groups of patients are needed.